An FDA advisory panel voted against the use of empagliflozin, an SGLT2 inhibitor, as an adjunct to insulin therapy in patients with type 1 diabetes. The potential risk of diabetic ketoacidosis with higher doses led the panel to say that the data did not show that the treatment's benefits outweigh the risks and an additional study is needed.
FDA panel votes against empagliflozin as insulin add-on in T1D
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.